The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease

Published Online:https://doi.org/10.1176/ajp.138.7.970

A double-blind, placebo-controlled trial of 2-dimethylaminoethanol was undertaken in 27 patients with moderately severe or severe Alzheimer's disease. Of 13 patients in the drug group, 6 were withdrawn in the first 5 weeks of the trial because of side effects, which included drowsiness and retardation, with an increase of confusion and mild elevation of blood pressure. No significant benefit appeared from the drug treatment.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.